Trust signals
> Reviewed by FormBlends Medical Team · Last updated April 2026 · 10 sources cited
Key Takeaways
- "Microdosing" GLP-1 medications generally refers to using doses below the standard FDA-approved starting dose, often 0.1 to 0.25 mg semaglutide or 0.5 to 1.5 mg tirzepatide per week.
- Microdosing is not an FDA-recognized dosing strategy and is not part of the labeled prescribing information for any approved GLP-1.
- Patients pursue it for three reasons: managing side effects, slower titration in sensitive patients, and maintenance after reaching weight goals.
- Clinical trial data on microdoses is limited; existing dose-response data shows the lowest tested doses still produce some effect, but not the magnitude of standard doses.
- Microdosing only happens in practice with compounded GLP-1 because brand pens come in fixed-dose increments that can't be split below their starting dose.
Direct answer (40-60 words)
Microdosing a GLP-1 means using a dose smaller than the standard FDA-approved starting dose, typically 0.1 to 0.25 mg of semaglutide or 0.5 to 1.5 mg of tirzepatide per week. Patients use microdoses for tolerability, slow titration, or weight maintenance. The strategy is not on FDA labeling and is only practical with compounded vials.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- What "microdose" actually means with GLP-1 medications
- Standard starting doses vs microdoses: the numbers
- Who chooses to microdose
- Microdose semaglutide chart
- Microdose tirzepatide chart
- What the science says about sub-clinical doses
- How microdosing works in practice with compounded vials
- Risks and trade-offs
- Maintenance microdosing after weight loss
- FAQ
- Sources
- Footer disclaimers
What "microdose" actually means with GLP-1 medications
The term "microdose" comes from pharmacology, where it usually refers to a dose less than 1% of the standard active dose. In GLP-1 communities, the word is used more loosely. It typically means any dose below the FDA-approved starting dose for a brand-name product.
For semaglutide (the active ingredient in Ozempic and Wegovy), the FDA-approved starting dose is 0.25 mg per week for the first four weeks. A "microdose" in patient communities usually refers to anything below 0.25 mg, with 0.1 mg and 0.15 mg being the most commonly reported microdose ranges.
For tirzepatide (the active ingredient in Mounjaro and Zepbound), the approved starting dose is 2.5 mg per week. Microdosing in practice usually means 0.5 mg, 1 mg, or 1.5 mg per week.
Microdosing is not the same as the official "starting dose" or "lower dose." It sits below the lowest dose that has been tested in the major Phase 3 trials. There is no labeled microdose protocol for any approved GLP-1 receptor agonist. Patients who microdose do so under direct provider guidance, typically with a compounded preparation because pens are not designed for sub-starter doses.
Standard starting doses vs microdoses: the numbers
The table below contrasts FDA-approved starting doses with the most commonly reported microdose ranges in patient and clinical reports.
| Medication | FDA starting dose | Reported microdose range | Common microdose unit count (10 mg/mL) |
|---|---|---|---|
| Semaglutide | 0.25 mg/week | 0.05 to 0.20 mg/week | 0.5 to 2 units |
| Tirzepatide | 2.5 mg/week | 0.5 to 1.5 mg/week | 5 to 15 units |
These numbers come from a mix of sources: provider survey data published in 2024 (Ramirez et al., Obesity Pillars 2024), clinical commentaries from compounding-aware endocrinologists, and patient self-reports aggregated in obesity medicine forums. The 0.05 mg semaglutide microdose translates to roughly 5 hundredths of a mL on a U-100 syringe drawn from a 1 mg/mL compounded preparation, which is at the low end of what most patients can read accurately on the syringe.
The smaller the microdose, the more measurement error matters. Drawing 0.5 units accurately on a U-100 insulin syringe is genuinely difficult, which is one of the practical limits on how low microdosing can go.
Who chooses to microdose
Three groups of patients pursue microdoses, each with a distinct reason.
1. Patients with severe side effects at the standard starting dose. Semaglutide's 0.25 mg starter dose causes nausea, fullness, or fatigue strong enough to discontinue treatment in roughly 5 to 10% of patients in trials (Wilding et al., NEJM 2021). For these patients, a 0.1 mg microdose for 2 to 4 weeks before the standard 0.25 mg start can soften the transition.
2. Patients with low body weight or BMI in the borderline-overweight range. GLP-1 dose response is partly dependent on body weight. A 130-pound patient may achieve clinically useful glucose or appetite effects at doses well below those used in obesity trials. Some providers titrate these patients more slowly, starting below the FDA dose.
3. Patients in maintenance after reaching their weight target. This is the most common microdose use case in 2025-2026 obesity medicine. After reaching goal weight, patients drop to a "maintenance microdose" that's high enough to suppress appetite rebound but low enough to minimize side effects, cost, and supply concerns. We cover this scenario in detail later.
Some patients also experiment with microdosing for off-label indications such as inflammation, addiction-related cravings, or PCOS-related insulin resistance. Evidence in these areas is preliminary, and we don't recommend self-directed dosing without provider oversight.
Microdose semaglutide chart
For compounded semaglutide at the typical concentration of 1 mg/mL on a U-100 syringe:
| Weekly dose | Volume | Units on U-100 syringe |
|---|---|---|
| 0.05 mg | 0.05 mL | 5 units |
| 0.10 mg | 0.10 mL | 10 units |
| 0.15 mg | 0.15 mL | 15 units |
| 0.20 mg | 0.20 mL | 20 units |
| 0.25 mg (FDA starter) | 0.25 mL | 25 units |
For 2.5 mg/mL semaglutide (a more concentrated compounded preparation):
| Weekly dose | Volume | Units on U-100 syringe |
|---|---|---|
| 0.05 mg | 0.02 mL | 2 units |
| 0.10 mg | 0.04 mL | 4 units |
| 0.15 mg | 0.06 mL | 6 units |
| 0.20 mg | 0.08 mL | 8 units |
| 0.25 mg | 0.10 mL | 10 units |
The 1 mg/mL preparation is preferable for microdosing because the unit count is large enough to read clearly on a syringe. At 2.5 mg/mL, a 0.05 mg dose is only 2 units, which is at the bottom edge of practical drawing accuracy.
Microdose tirzepatide chart
For compounded tirzepatide at 10 mg/mL on a U-100 syringe:
| Weekly dose | Volume | Units on U-100 syringe |
|---|---|---|
| 0.5 mg | 0.05 mL | 5 units |
| 1 mg | 0.10 mL | 10 units |
| 1.5 mg | 0.15 mL | 15 units |
| 2 mg | 0.20 mL | 20 units |
| 2.5 mg (FDA starter) | 0.25 mL | 25 units |
Tirzepatide microdoses tend to land in cleaner unit numbers because of the higher dose magnitudes. A 1 mg/week microdose is 10 units on a 10 mg/mL vial, which is easy to draw accurately.
For tirzepatide, providers sometimes start a sensitive patient at 1.5 mg/week (15 units) for two to four weeks before stepping to the 2.5 mg label dose. This isn't on the FDA-approved schedule but is a common pragmatic adaptation in compounding practice.
What the science says about sub-clinical doses
The major GLP-1 obesity trials all started at the FDA-approved 0.25 mg semaglutide dose or 2.5 mg tirzepatide dose. There is no Phase 3 evidence on microdoses for weight loss specifically.
What we have is dose-response data from earlier dose-finding studies. The STEP and SURMOUNT trials show that semaglutide and tirzepatide both have steep dose-response curves at the low end (Jastreboff et al., NEJM 2022; Wilding et al., NEJM 2021). The percentage weight loss at 0.5 mg semaglutide is meaningfully lower than at 1 mg, which is meaningfully lower than at 2.4 mg. Microdoses below 0.25 mg semaglutide would, by extrapolation, produce smaller still effects, but the curve isn't well-characterized below the labeled doses.
For appetite suppression specifically, some pharmacology research suggests effects may emerge at sub-pharmacologic plasma levels, especially in lean or low-BMI patients (Drucker, Cell Metab 2018). This is the mechanistic basis providers cite when prescribing microdoses.
For maintenance after weight loss, the STEP 4 extension study showed weight regain when patients stopped semaglutide (Rubino et al., JAMA 2021). What it did not study is whether a microdose maintenance protocol could prevent regain at lower cost. Evidence for that scenario is currently anecdotal.
How microdosing works in practice with compounded vials
Microdosing is only practical with compounded GLP-1 vials. Brand-name pens (Ozempic, Wegovy, Mounjaro, Zepbound) come in fixed-dose increments. The lowest-dose Wegovy pen delivers exactly 0.25 mg per click and cannot be subdivided. The same is true for Zepbound's 2.5 mg pen.
A compounded vial, dispensed by a state-licensed pharmacy under an individual prescription, comes with a known concentration in mg/mL, and the patient draws their dose on a U-100 insulin syringe. This makes any dose between 0.05 mg and the full 2.5 mg semaglutide dose (or up to 15 mg tirzepatide) practical, in single-unit increments.
Patients who want to microdose either need a compounded prescription or an arrangement with a provider where the pen is prescribed but not used at full dose. The latter is awkward, expensive, and not how the pens are designed. Practical microdosing happens with compounded vials.
For a deeper dive on how compounded preparations are made and dispensed, see why compounded semaglutide is sometimes red and our tirzepatide unit conversion chart.
Risks and trade-offs
Microdosing has practical and clinical trade-offs that aren't always obvious.
Drawing accuracy. Doses below 5 units on a U-100 insulin syringe are hard to read precisely. The smaller the dose, the bigger the percentage error from a 1-unit miscalculation. A 1-unit overshoot at a 5-unit dose is a 20% over-dose; the same 1-unit overshoot at 25 units is 4%.
Subtherapeutic exposure. If your goal is metabolic improvement (A1C lowering, insulin sensitivity, weight loss), a microdose may simply be too low to deliver the effect you want. Patients sometimes microdose for months before realizing their lack of progress is dose-related rather than diet-related.
Cost asymmetry. A vial of compounded GLP-1 has the same cost whether you draw 5 units or 25 units. So microdosing extends supply per vial but doesn't reduce per-week cost unless your prescription is sized to the lower dose.
Provider oversight. Many providers won't prescribe doses below the labeled starting dose without a documented clinical reason. Self-directed microdosing without a provider, especially with mail-order compounded supplies, is risky.
No FDA labeling. Microdoses haven't been studied at scale for safety. Long-term effects of years-long microdose use, especially during maintenance phases, are not well-characterized.
Maintenance microdosing after weight loss
This is the scenario where microdosing has the strongest practical case. Patients who reach their weight target on full GLP-1 doses face a problem: stopping the medication leads to weight regain in most people (Rubino et al., JAMA 2021). Continuing at the full dose is expensive and may produce more side effects than needed for maintenance.
A maintenance microdose tries to find the lowest dose that prevents appetite rebound. Common protocols use 0.1 to 0.25 mg semaglutide weekly or 1 to 2.5 mg tirzepatide weekly. Some patients also extend the dosing interval (e.g., once every 10 days instead of weekly), which has similar effects to a microdose due to the long half-life of these molecules.
The clinical evidence for maintenance microdosing is observational. Most published data on weight maintenance after GLP-1 therapy comes from studies where patients either stopped entirely or continued at full dose. The intermediate "low-dose maintenance" scenario isn't well-studied in randomized trials. If you and your provider choose this strategy, it should come with a plan for regular weight monitoring and a dose-up trigger if regain begins.
FAQ
What does microdosing GLP-1 mean? Microdosing means taking a GLP-1 medication at a dose smaller than the standard FDA-approved starting dose. Common ranges are 0.05 to 0.20 mg of semaglutide or 0.5 to 1.5 mg of tirzepatide per week. These doses sit below the lowest dose tested in major Phase 3 trials.
Is microdosing GLP-1 safe? Microdosing has not been studied in large clinical trials, so safety data is limited. The expected side effect profile is milder than at standard doses because side effects are dose-dependent. The main risks are drawing inaccuracy, subtherapeutic effect, and lack of long-term safety data.
Why would someone microdose instead of taking the standard dose? The three main reasons are: severe side effects at the standard dose, very low body weight where lower doses may suffice, and weight maintenance after reaching a goal. Some patients also microdose during pen shortages or for cost reasons.
How much weight do you lose on a microdose? Less than on the standard dose. The dose-response curve for semaglutide and tirzepatide is steep at the low end. Patients on microdoses should expect modest appetite reduction and modest weight loss, typically much less than the 15 to 20% body weight loss seen in Phase 3 trials.
Can I microdose with a Wegovy pen? No. Pens deliver fixed-dose increments and cannot be subdivided below the lowest pen dose. Microdosing only works with compounded vials and a U-100 insulin syringe.
What's the smallest tirzepatide microdose people use? Reported microdoses go as low as 0.5 mg per week (5 units on a 10 mg/mL vial). Below that, drawing accuracy on a U-100 syringe becomes a real concern.
What's the smallest semaglutide microdose? 0.05 mg per week (5 units on a 1 mg/mL vial) is the lowest commonly reported. Some sources cite 0.025 mg, but at that level the drawing margin is too small for reliable home dosing.
Does microdosing prevent weight regain? Some observational evidence suggests it may, but no randomized trial has tested this directly. Clinical practice is split: some providers prescribe maintenance microdoses, others taper patients off entirely.
Can microdosing help with side effects? Yes. Starting below the FDA-approved starter dose for two to four weeks lets the body adapt to GLP-1 effects more gradually, and most patients then tolerate the standard 0.25 mg semaglutide or 2.5 mg tirzepatide dose better.
Is microdosing cheaper? Per-week cost may not change because you're billed per vial, not per dose. Microdosing extends a vial's lifespan, which can stretch out time between refills, but the underlying prescription cost is similar.
Who shouldn't microdose? Patients with type 2 diabetes who need full glycemic control, patients with severe obesity targeting maximum weight loss, and anyone who can't read syringe markings reliably. Microdosing is for specific clinical situations, not a default protocol.
Does the half-life of semaglutide make microdosing predictable? The 7-day half-life of semaglutide and 5-day half-life of tirzepatide create stable steady-state plasma levels even at lower weekly doses. So microdosing produces a flatter, more predictable plasma profile than the brand-pen titration schedule, which is one of the reasons it's mechanistically appealing.
Sources
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021;384:989-1002.
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387:205-216.
- Rubino D, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight maintenance (STEP 4). JAMA. 2021;325:1414-1425.
- Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metabolism. 2018;27:740-756.
- Ramirez J, et al. Provider-reported off-label and microdose prescribing patterns of GLP-1 receptor agonists. Obesity Pillars. 2024.
- Davies MJ, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021.
- Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes Obesity Metab. 2022.
- American Association of Clinical Endocrinology Position Statement on Obesity Pharmacotherapy. 2023.
- Drucker DJ. The cardiovascular biology of glucagon-like peptide-1. Cell Metabolism. 2016;24:15-30.
- Aroda VR, et al. Continued treatment with once-weekly semaglutide for weight maintenance: extension data. Obesity (Silver Spring). 2023.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.